Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer

Future Oncol. 2013 Jun;9(6):899-907. doi: 10.2217/fon.13.50.


Aim: Sarcosine has been identified as a differential metabolite that is greatly increased during progression from normal tissue to prostate cancer and metastatic disease. In this study we assessed the role of serum sarcosine in metastatic castration-resistant prostate cancer (mCRPC) patients.

Patients & methods: Data from 52 mCRPC patients treated with docetaxel-based chemotherapy were retrospectively analyzed. Receiver operating characteristic curves, and Kaplan-Meier and Cox multivariate analyses were performed.

Results: Median sarcosine values were significantly higher in mCRPC versus non-mCRPC patients (0.81 vs 0.52 nmol/µl; p < 0.0001). A significant correlation resulted between serum sarcosine levels and the duration of hormone sensitivity (Spearman's correlation coefficient: -0.51; p = 0.001). At multivariate analysis sarcosine was an independent prognostic factor of outcome in terms of overall and progression-free survival.

Conclusion: Serum sarcosine values were significantly increased in patients with metastatic disease. Moreover, this biomarker is a risk factor for progression and survival in chemotherapy-treated mCRPC patients.

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Biomarkers, Tumor / blood
  • Castration
  • Disease-Free Survival
  • Docetaxel
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Metastasis / pathology
  • Neoplasm Staging
  • Proportional Hazards Models
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Risk Factors
  • Sarcosine / blood*
  • Taxoids / administration & dosage*


  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Taxoids
  • Docetaxel
  • Sarcosine